Global PharmaBoardroom has spread its wings far and wide in 2021 (albeit digitally!), from well covered markets such as Singapore and Switzerland to new frontiers like Saudi Arabia. Our interviewees have ranged from regional Big Pharma and medtech general managers, to the CEOs of important local players, and the heads of…
Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of the company from 30 to 300 employees. Here, he shares his insights on why M&A may be a better strategy…
Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a Switzerland-based specialty pharma player focused on the digestive system, shares his M&A principles and insights, their exciting recent acquisition of DIFICLIR™ from Astellas, and the company’s recognition as a Great Place to Work® (GPTW) in Switzerland. For…
Switzerland In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at punching well above their weight. After the giants, Roche and Novartis, some of the larger companies in the Swiss pharma sector like Ferring and IBSA are privately held,…
France Edouard Bieth, managing director of Tillotts Pharma in France, discusses the opportunities and challenges of opening an affiliate in the country and the uniqueness of Tillotts’ specialization in gastrointestinal drugs. Tillotts France may be young but the expertise within GI has been established on a global scale over decades…
Spain Sergio Serra Ripol, managing director of Tillotts Pharma Spain, highlights the challenges associated with setting up the affiliate and the strategic importance of Spain as Tillotts grows its European footprint. Furthermore, he gives an insight into the importance of relationships in building the company’s network and his vision for the…
United Kingdom Jeremy Thorpe established Tillotts Pharma’s operations in the UK, building his team around the central pillar of customer relationships. Jeremy explains how his company’s approach allowed it to reach £25 million in sales and market leadership with Octasa® in just six years. What is the history of Tillotts Pharma in…
Switzerland Backed by the Japanese Zeria Group, fast growing gastrointestinal (GI) specialist Tillotts Pharma is looking to acquire further GI assets after its recent USD 200m M&A deal. The company is looking for assets which generate a turnover of EUR 50 – 150 million in Europe and/or Japan, and also to…
Tillotts Ireland Can you give us a sense of the history of this company and its Irish roots? The company started life in the UK and has always been a GI franchise company. We specialized in two products when we began: Colpermin®, for the symptomatic treatment of bowel spasms and bloating in…
See our Cookie Privacy Policy Here